{"id":"kw-2246-fentanyl-citrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Dependence/addiction risk"}]},"_chembl":{"chemblId":"CHEMBL688","moleculeType":"Small molecule","molecularWeight":"528.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fentanyl is a synthetic opioid agonist that acts primarily on mu (μ) opioid receptors in the brain and spinal cord. By activating these receptors, it modulates pain perception and transmission, providing potent analgesia. KW-2246 represents a formulation or delivery approach of this well-established opioid mechanism, likely developed by Kyowa Kirin for specific clinical applications.","oneSentence":"KW-2246 is a fentanyl citrate formulation that binds to opioid receptors in the central nervous system to produce analgesia and pain relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:57.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT00684632","phase":"PHASE3","title":"A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2008-03","conditions":"Pain, Cancer","enrollment":51},{"nctId":"NCT00683995","phase":"PHASE3","title":"A Phase III Clinical Study of KW-2246","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2008-03","conditions":"Pain, Cancer","enrollment":43},{"nctId":"NCT00355628","phase":"PHASE2","title":"Clinical Study of KW-2246 in Patients With Cancer Pain","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-07","conditions":"Pain, Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":448,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fentanyl citrate"],"phase":"phase_3","status":"active","brandName":"KW-2246 (fentanyl citrate)","genericName":"KW-2246 (fentanyl citrate)","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KW-2246 is a fentanyl citrate formulation that binds to opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Moderate to severe pain (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}